Most Recent Annual Report
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
2019 Annual Report and Form 10K
Immunic, Inc. has reached its limit for free report views.
Work for Immunic, Inc.?
Claim Your Profile
Immunic, Inc.
About Immunic, Inc.
11-50 Employees
Based in New York City, New York
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. Immunic is developing three small molecule products: its lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function.
- Ticker:
- IMUX
- Exchange:
- NASDAQ (See More NASDAQ Companies)
- Industry:
- Biotechnology (See More Biotechnology Companies)
- Sector:
- Healthcare (See More Healthcare Companies)
